Could 'Peacekeeper' cells free liver transplant patients from lifelong drugs?
NCT ID NCT03577431
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether infusing specially grown donor-specific regulatory T cells (Tregs) can allow liver transplant recipients to safely reduce or stop their anti-rejection medications. Nine participants will receive a single dose of these cells and be monitored for side effects and whether they can maintain a healthy liver without standard immunosuppression. The goal is to see if this cellular therapy can induce 'operational tolerance'—a state where the body accepts the donor organ without needing lifelong drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor-specific regulatory T cells (arTreg-CSB)
What this could lead to
If successful, this could allow some liver transplant recipients to stop or reduce lifelong anti-rejection medication without rejecting the organ.
What could go wrong
This is a very early, tiny trial (9 people) focused on safety, not proof of effectiveness. The approach may not work or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital: Transplantation
Boston, Massachusetts, 02114, United States